NEW YORK (Reuters Health) - Patients with hepatocellular carcinoma (HCC) have a significantly higher prevalence of type 2 diabetes mellitus (DM) compared to the general population, according to findings from a case-control study conducted in Italy.
"The association of type (DM2) ... with hepatocellular carcinoma (HCC) has been long suspected," Dr. Valter Donadon, at Pordenone Hospital, and co-authors note in the October 7 issue of the World Journal of Gastroenterology. "However, the temporal relationship between... read more
Submitted by Avera
Children and adolescents like to spend their leisure time with friends, going to the cinema, doing sport and trying out all sorts of things as they grow up. Jessica Gagnoux from Geneva was no different. But then the young girl's world was turned upside down when her doctor diagnosed Type 1 diabetes. The eleven-year-old's pancreas had stopped producing the vital hormone insulin. "Within a short space of time, I had lost ten kilos. I felt... read more
Submitted by Avera
NEW YORK, Nov 14, 2008 /PRNewswire via COMTEX/ -- US-Specific DAWN Youth WebTalk Survey Data Released on World Diabetes Day at Youth Forum
Data from a new global survey released on World Diabetes Day finds that many teens and young adults with type 1 diabetes are optimistic about their future, but report a lack of support from school staff. The poll highlights the importance of family and peer-to-peer support.
The DAWN Youth WebTalk... read more
Submitted by Avera
BETHESDA, Md., Nov. 14 /PRNewswire/ -- A new study presented today at the Annual Meeting of the Diabetes Technology Society showed that changes in the position of a conventional insulin pump, relative to its infusion set, can significantly impact expected insulin delivery rates. Such changes may occur during routine daily activities such as getting dressed, sleeping or showering. This siphon effect has been reported previously in hospital IV pumps, but this is the first time... read more
Submitted by Avera
WORCESTER, Mass. and MUMBAI, India, Nov 14, 2008 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (GNBT:generex biotechnology cp del com
News, chart, profile, more
Last: 0.35+0.01+2.94%
3:59pm 11/14/2008
Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GNBT 0.35, +0.01, +2.9%) ( www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, and Shreya Life Sciences Pvt.... read more
Submitted by Avera
Even though a slew of new medical devices launched over the past decade now help kids with type 1 diabetes better manage their disease, a new survey indicates those touched by childhood diabetes still seek more support from schools and about half of young people with the condition have trouble coping.
More than 9,000 people worldwide responded to The DAWN Youth WebTalk Survey online, including about 2,000 Americans. The 3 primary groups polled included... read more
Submitted by Avera
Advertisement
A third of type one diabetics dice with danger by skipping insulin injections to shed weight, an Australian study has found.
Research by Diabetes Australia Victoria has found that 33 per cent of patients skip insulin injections, with almost half doing so on a daily basis.
More than a quarter missed a dose every week.
Most admitted reducing their insulin dose in a risky bid to lose weight and gain control over their... read more
Submitted by Avera
The health of many children with type 1 diabetes is threatened due to poor care in primary schools, say campaigners.
Diabetes UK claims 6,500 pupils in England are not covered by school medication policies which ensure they get insulin injections when needed.
This means parents often need to visit during the school day to administer injections.
The charity wants ministers to force school inspectors to keep checks on the care of children... read more
Submitted by Avera
DUBLIN, Ireland, Nov 11, 2008 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/9c5db8/competitor_analysi) has announced the addition of the "Competitor Analysis: Diabetes Drug Pipeline" report to their offering.
This Competitive Intelligence report on the Diabetes Drug Pipeline, as of November 2008 provides a competitor analysis in the development pipeline of novel antidiabetic treatment modalities for type 1 and 2 diabetes. The report includes an overview of the major marketed diabetes drugs and the respective... read more
Submitted by Avera
These days, Doug Burns is a modern Sampson. The reigning Mr. Universe, he’s two hundred pounds of sheer muscle and the picture of good health. Of the skinny little boy with type 1 who used to work out in the woods alone, all that remains are a wry sense of humor and an attractively self-deprecating manner. They’re unexpected in a man who’s triumphed in the uber-masculine world of bodybuilding, but there’s a lot that’s unexpected... read more
Submitted by Avera